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Background: Little is known about the clinical patterns of vitiligo and its associations in Arab countries, particularly Saudi Arabia.
Methods: We performed a retrospective review of 135 medical records of patient with vitiligo seen at the Hera Hospital, Makkah,
Saudi Arabia between January 2010 and June 2013.
Results: Of the 135 patients (mean age, 24.5 years), 91 (67.4%) were females. Twenty-six patients (25%) had a positive family history,
12.6% with associated thyroid disorders, 9.6% diabetes mellitus, 8.9% atopic dermatitis, 3.7% leukotrichia, and 2.2% alopecia areata.
Sixty percent of patients had localized vitiligo, 37% generalized, 9.6% acrofacial, and 1.5% universal. The commonest site for the ﬁrst
vitiligo lesion was the face (28% of patients), whereas the commonest site at the time of diagnosis was the lower limb (51% of cases).
The commonest topical treatment for localized vitiligo was tacrolimus (34.8%), whereas narrow band ultraviolet B (14%) had most com-
monly been prescribed for those with generalized vitiligo.
Conclusions: The patients were predominantly females, with a large proportion having a positive family history. The mean age of
onset of vitiligo in our study was 24.5 years. It was commonly associated with thyroid disorders. Localized vitiligo was the most prevalent
type.
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Vitiligo is a common disorder of skin pigmentation.
The prevalence rages from 0.1% to 4% and is estimated
to be about 1% in white individuals (Lerner, 1971). In
Saudi Arabia, 40% of dermatologists reportedly seeing
from 5 to 10 vitiligo patients per week, 12.6% seeing
more than 10 patients per week (AlGhamdi, 2009).
Because 30% of patients have a positive family history,
a causative genetic component is likely (Kostovic and
Pasic, 2005). Studies of both twins and whole families
have provided evidence for the importance of a genetic
role in vitiligo development (Passeron and Ortonne,
2005; Zhang et al., 2005).Saud University.
ommons.org/licenses/by-nc-nd/3.0/).
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be dependent on an interaction between genetic, immuno-
logical and neurological factors (Whitton et al., 2008). In
general, vitiligo has a multifactorial etiology and polygenic
inheritance. The most likely theory about causation pro-
poses that alterations in humoral or cellular immunity
result in autoimmune processes attacking the melanocytes,
causing non-functioning or absence of melanocytes in the
aﬀected area (Van den Wijngaard et al., 2000). Vitiligo is
divided into several types based on its distribution pattern:
localized, segmental, generalized, mucosal, acrofacial, and
universal.
The diagnosis of vitiligo depends on history and physi-
cal examination, which reveals depigmented skin patches
or lesions. In some challenging cases, such as vitiligo in
lightly pigmented patients, a Wood’s lamp can be useful
for highlighting areas of pigment loss.
There are many options for treating vitiligo. Medical
therapies include photochemotherapy, phototherapy with
ultraviolet B (UVB) radiation (broadband and narrow-
band), topical steroids, systemic steroids, topical immuno-
modulators (tacrolimus and pimecrolimus), vitamin D3
analogs, and excimer laser (Kostovic and Pasic, 2005).
The aim of this study was to evaluate the clinical fea-
tures of vitiligo and its associated comorbidities in Saudi
Arabia, a topic about which there is little reported data.2. Materials and methods
We performed a retrospective review of the medical
records of 135 vitiligo patients who attended the dermatol-
ogy outpatient clinic of Hera General Hospital in Makkah,
Saudi Arabia, from January 2010 to June 2013. We
enrolled all vitiligo patients in the study with no exclusions
based on sex, nationality, city of residence, or socioeco-
nomic status. The diagnosis of vitiligo was made clinically.
We developed a data collection form to facilitate collection
of relevant clinical and other data on sex, age of vitiligo
onset, each patient’s Fitzpatrick skin type, family history
of vitiligo, family history of premature graying of scalp
hair, associated diseases, precipitating factors, location of
the ﬁrst lesion, type of vitiligo, location of lesions, presenceTable 1
Family history of vitiligo according to age group.
Age group (years) Family history of vitiligo
1st-degree relative 2nd-degree relative 3
0–10 3 2 1
11–20 8 2 0
21–30 5 0 0
31–40 3 0 0
41–50 1 0 0
51–60 0 1 0
61–70 0 0 0
71–80 0 0 0
Total 20 (19%) 5 (4.8%) 1
* Cases for which data were unavailable were not included in the statisticalof trichrome, treatment modalities, and response to
treatment.
In our study, we used Statistical Package for Social Sci-
ences software, version 20, for data entry and analysis.
Continuous data are presented as means. Categorical vari-
ables are presented as frequencies and percentages. Our
study was designed around ethical considerations of jus-
tice, autonomy, and beneﬁcence. The research proposal
was approved by the Research Ethics Committee of the
Hera General Hospital in Makkah, Saudi Arabia.3. Results
In all, 31,342 patients were seen in the dermatology
department of Hera General Hospital, Makkah, Saudi
Arabia from January 2010 to June 2013. Among those
patients, 135 had vitiligo; thus, its incidence was 0.43%.
Female patients were in the majority, comprising 91
(67.4%), with the male to female ratio therefore being 1–
2.06. The patients ranged in age from 1 to 76 years, with
a mean age of 24.5 years. Twenty-six patients (25%)
reported that other members of the family had vitiligo,
19% of aﬀected patients and their family members being
ﬁrst-degree relatives. There was a positive correlation
between family history of premature graying of scalp hair
and vitiligo in 7.27% of the patients. Table 1 shows the cor-
relations between age groups and family history of vitiligo.
The main type of triggering factor was physical factors
such as trauma (Koebner phenomenon) (8% of patients).
The next most common precipitating factor was illness
(5% of patients). Pregnancy and emotional factors were
reported by 3% of patients and a history of severe sunburn
by 2%.
Associated autoimmune/endocrine disorders were pres-
ent in the majority of the patients. Of these, thyroid disor-
der was the most common, being reported in 12.6% of
patients and followed by diabetes mellitus in 9.6%, rheu-
matoid arthritis in 2.2%, and multiple sclerosis in 0.7%.
None of our patients had pernicious anemia. Other comor-
bidities included cardiac problems in 8.9%, bronchial
asthma in 5.9%, hearing problems in 3.7%, and systemic
lupus erythematosus in 0.7% of patients. The associatedTotal (%)
rd-degree relative No family history Not reported*
20 7 33 (24.4)
19 8 37 (27.4)
16 3 24 (17.8)
9 1 13 9.6)
6 6 13 (9.6)
4 2 7 (5.2)
4 2 6 (4.4)
1 1 2 (1.5)
(1%) 79 30 135 (100)
analysis.
Table 2
Distribution of age group according to type of vitiligo.
Age group (years) Type of vitiligo Total
Generalized Segmental Localized Acrofacial
1–15 27 2 27 0 56 (41.5%)
16–30 10 0 27 1 38 (28.2%)
31–45 6 0 15 0 21 (15.5%)
46–80 7 0 13 0 20 (14.8)
50 (37%) 2 (1.5%) 82 (60.7%) 1 (0.8%) 135 (100%)
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tis in 8.9%, pruritus in 5.2%, leukotrichia in 3.7%, alopecia
areata in 2.2%, and psoriasis and mycosis fungoides in
0.7% of patients.
Vitiligo is classiﬁed clinically into generalized, segmen-
tal, localized, acrofacial, mucosal, and universal types.
Table 2 shows the types of vitiligo according to the age
group. Contrary to expectations, there were no patients
with the mucosal type of vitiligo in this study.
The most common site of the ﬁrst vitiligo lesion was the
face (total 28%; peri-orbital area 7.4%, peri-oral area 3.7%,
the area of the nose 0.7%, and other areas of the face
19.3%). The next most common sites were the right lower
limb (20%), left lower limb (15.6%), right hand (12.6%), left
upper limb (9.6%), left hand (8.9%), left foot (8.9%), right
upper limb (8.1%), neck (7.4%), right foot (5.9%), abdomen
(5.2%), back (3%), scalp (2.2%), genitals (2.2%), chest
(0.7%), and buttocks (0.7%).
At the time of diagnosis, the most commonly involved
part of the body was the right lower limb (51%), followed
by the face (49%; speciﬁcally, 14% in the peri-orbital area,
12.6% in the peri-oral area, 5.9% in the area of the nose,
and 26.6% in the other areas of the face), left lower limb
(45%), right upper limb (37%), right hand (25.9%), left foot
(25.2%), left hand (23.7%), right foot (22.2%), chest
(16.3%), back (15.6%), neck (13.3%), abdomen (12.6%),
genitals (8.9%), buttocks (4.4%), and scalp (3.7%).
The vitiligo lesions were symmetrically distributed in
just over half of the patients (54%). Trichrome lesions, or
lesions that consist of a tan zone of varying width between
the normal and depigmented skin, were present in 21.27%
of cases. Spontaneous repigmentation of depigmented skin
occurred in 22% of the patients.Table 3
Treatment according to clinical type of vitiligo.
Treatment modality Type of vitiligo
Generalized Segmental
Topical steroids 22 (16.3) 2 (1.5%)
Tacrolimus 31 (23%) 1 (0.7%)
Vitamin D analog 6 (4.4%) 0
Narrow band UVB 19(14.1%) 0
Psoralen plus UVA 2 (1.5%) 0
Methoxsalen plus sunlight 0 1 (0.7%)
Excimer laser 7 (5.2%) 0
Systemic steroids 2 (1.5%) 1 (0.7%)The goals of vitiligo treatments are repigmentation of
the depigmented lesions and prevention of further progres-
sion of the disease. Table 3 shows treatment modalities
according to clinical type of vitiligo.4. Discussion
The incidence of vitiligo in our study was 0.43%, which
is lower than the 2.5% reported for the King Khalid Uni-
versity Hospital, Riyadh, Saudi Arabia (Jarallah et al.,
1993). This may be attributable to the fact that it is a ter-
tiary care hospital with all treatment modalities available.
The incidence found in our study is comparable to those
reported for Denmark 0.36% (Howitz et al., 1977), Cal-
cutta 0.46% (Das et al., 1985), and Libya 0.33% (Singh
et al., 1985).
In accordance with other studies, the disease occurred
predominantly in female patients in our sample (Shajil
et al., 2006; Shah et al., 2008; Sedighe and
Gholamhossein, 2008). In contrast, three studies have
reported that vitiligo occurs predominantly in male individ-
uals (Shankar et al., 2012; Gopal et al., 2007; Dave et al.,
2002). This discrepancy has been attributed to a presumed
increase in reporting of cosmetic concerns by female
patients.
In our patients, the age of onset varied widely, from one
to seventy-six years, with a mean age of onset of 24.5 years.
This age of onset is slightly lower than the 25.59–32.4 years
reported by several other general population-based studies
(Shajil et al., 2006; Shankar et al., 2012; Ary´can et al., 2008;
Reghu and James, 2011). Only one study has reported a
lower mean age of onset, namely 23 years (Gopal et al.,
2007). It seems that the age of onset of vitiligo may diﬀerTotal
Localized Acrofacial
42 (31%) 1 (0.7%) 67 (49.5%)
47(34.8%) 0 79 (58.5%)
6 (4.4%) 0 12 (8.8%)
8 (5.9%) 0 27 (20%)
1 (0.7%) 0 3 (2.2%)
5 (3.7%) 0 6 (4.4%)
19 (14.1%) 0 26 (19.3%)
1 (0.7%) 0 4 (2.9%)
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cases appeared before the age of 20 years, which is compa-
rable to other studies (Szczurko and Boon, 2008; Halder
and Nootheti, 2003; Behl and Bhatia, 1971). Onset rarely
occurs in infancy or old age (Lotti et al., 2008) and the inci-
dence decreases with increasing age (Tonsi, 2004).
A positive family history of vitiligo was reported by
24.8% of our patients. This is a slightly higher percentage
than the 7.5–21.93% reported by several other studies
(Shajil et al., 2006; Shah et al., 2008; Shankar et al.,
2012; Dave et al., 2002; Ary´can et al., 2008; Reghu and
James, 2011; Behl et al., 1994). As has previously been
pointed out, our study conﬁrms that vitiligo occurs more
frequently in patients with a ﬁrst-degree family history of
this condition (Shankar et al., 2012; Gopal et al., 2007;
Reghu and James, 2011).
As previously noted, the most frequent type of factor
precipitating vitiligo is physical factors, or what is known
as the Koebner phenomenon (Reghu and James, 2011).
In our study, only 2% of the patients reported an associa-
tion between severe sunburn and vitiligo. Although this
percentage diﬀers markedly from other reports citing devel-
opment of vitiligo after severe sunburn in 20% of patients,
it is consistent with the skin type of our population
(Nordlund, 1982). As other authors have previously
pointed out, both vitiligo and thyroid disorders are signif-
icantly associated with diabetes mellitus (Reghu and James,
2011). One unanticipated ﬁnding of our study was that we
identiﬁed no patients in whom vitiligo was associated with
halo nevus, pernicious anemia, idiopathic guttate hypomel-
anosis, or tinea cruris, in contrast with the ﬁndings of ear-
lier studies (Ary´can et al., 2008; Reghu and James, 2011).
Surprisingly, this is the ﬁrst study to associate vitiligo with
mycosis fungoides and multiple sclerosis. These ﬁndings
should be interpreted with caution.
Given that all previous research has found the general-
ized type to be the most common type of vitiligo (Shajil
et al., 2006; Shah et al., 2008; Shankar et al., 2012;
Ary´can et al., 2008; Reghu and James, 2011; Behl et al.,
1994; Martis et al., 2002), it is somewhat surprising that
the most prevalent clinical pattern in our patients was the
localized type. We found a broad spectrum of aﬀected ana-
tomical sites. In our study, the commonest initial site of
involvement was the head and neck (37.6% of all patients),
in contrast with the ﬁndings of Reghu, who reported that
the lower limbs were the commonest initial site to develop
depigmentation (Reghu and James, 2011). A possible
explanation for this discrepancy is that in our culture the
head and neck are exposed, whereas most other parts of
the body are covered.
Published reports give varying percentages for the inci-
dence of trichrome in vitiligo patients. One Indian study
reported trichrome lesions in 66.3% of their study sample
(Ary´can et al., 2008), whereas an Egyptian study reported
trichrome lesions in 7.8% of vitiligo patients (Altaf at al.,
2010). We found trichrome in 21.27% of our patients. In
addition, spontaneous repigmentation occurred in 22% ofour patients. This is consistent with previous reports, which
cited rates of spontaneous repigmentation of vitiligo areas
in 10–20% of patients (Lotti et al., 2008; Castanet and
Ortonne, 1997).
This study documented the use of diﬀerent modalities in
the treatment of vitiligo: in order of frequency of use, these
modalities were tacrolimus, topical steroids, narrow band
UVB phototherapy, excimer laser, calcipotriene, methoxsa-
len and psoralen plus UVA. This wide range of treatment
modalities can be explained not only by diﬀerent types of
vitiligo but also by diﬀerent sites of body involvement. In
our study, tacrolimus was more likely to be used in patients
with localized vitiligo, whereas narrow band UVB photo-
therapy was more often used in patients with generalized
vitiligo. This ﬁnding is consistent with the previous
research on the use of topical calcineurin inhibitors for vit-
iligo repigmentation (Grimes et al., 2002, 2004; Travis
et al., 2003).
5. Conclusion
This study achieved our stated purpose of determining
the clinical patterns of vitiligo and its associated comorbid-
ities in order to report the main features of this disease in
Saudi Arabia. In our study, vitiligo occurred more com-
monly in female individuals. The mean age of onset of vit-
iligo was 24.5 years and the disease occurred more
frequently in patients with a ﬁrst-degree family history of
vitiligo. Physical factors were the most frequent type of
precipitating factor. Vitiligo was commonly associated with
thyroid disorders and diabetes mellitus. The most impor-
tant ﬁnding to emerge from this study is that localized vit-
iligo was the most prevalent type of vitiligo in our study
sample. This research has raised many questions in need
of further investigation, such as the association between
vitiligo and mycosis fungoides and multiple sclerosis.
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